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Abstract
Background: Awareness of the spectrum of clinical manifestations of systemic lupus erythematosus (SLE), especially
uncommon changes, is essential for diagnosis and effective management of patients.
Case presentation: A 26-year-old Chinese man with SLE initially manifested cutaneous papulonodular mucinosis
and developed acute Guillain-Barré syndrome and class V lupus nephritis 2 years later. His cutaneous nodules had
not been idententified for 2 years and were resected by surgical procedures twice until SLE was diagnosed.
The kidney biopsy revealed class V lupus nephritis. The patient responded well to a short course of intravenous
immunoglobulins and his muscle strength almost completely recovered. So far, he has undergone five cycles of
cyclophosphamide combined with hydroxychloroquine and tapering prednisone, resulting in partial remission of lupus
nephritis and disappearance of hypocomplementemia.
Conclusion: We reported a rare case of male patient with SLE with manifestation of class V lupus nephritis, Guillain-Barré
syndrome and papulonodular mucinosis.
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Background
Systemic lupus erythematosus (SLE) is a complex multi-
system autoimmune disease presenting with a wide
spectrum of clinical and immunological abnormalities
[1]. Skin involvement occurs in more than 85% of lupus
erythematosus (LE) cases, and the four classic presenta-
tions include malar rash, discoid rash, photosensitivity
and oral mucosal lesions [2]. Lupus-related polyneurop-
athy have been reported in 10–20% of patients with SLE
[3]. Many different types of neuropsychiatric symptoms
occur in patients with SLE. The kidney is also one of
most frequently involved organs. The reported incidence
of clinically important kidney diseases in systemic lupus
varies widely, range from 12 to 69% [4]. However, patients
with SLE may present with an array of manifestations not
limited to these common presentations, such as Guillan
Barré syndrome (GBS), papulonodular mucinosis (PNM)
and class V nephritis which are all rarer associations in
SLE than describing in general about neurological, muco-
cutaneous manifestations and renal involvement in SLE.
Awareness of the spectrum of clinical manifestations of
SLE, especially uncommon changes, is essential for diag-
nosis and effective management of patients. We describe a
rare case of SLE in a patient who initially had cutaneous
PNM and had not been identified for 2 years until GBS
and class V lupus nephritis were detected.
Case presentation
A 26-year-old Chinese man presented with progressive
numbness, weakness and paresthesia of the extremities.
One month before admission, he began to complain of
mild symmetrical numbness, weakness and paresthesia
of limbs (with “socks and gloves” distribution). Simul-
taneously, he was found to have transient facial
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erythema after exposed to ultraviolet light, which disap-
peared spontaneously without treatment. One week
before admission, his numbness and weakness in lower
extremities progressed to limit his ambulation. His
medical past history was notable for isolated nodular
masses twice without pain in the cheeks below the left
and right earlobe in 2013 and 2014, which were 4 × 5 cm
(left) in 2013 and 3 × 3 cm (right) in 2014. They were both
resected with a pathological diagnosis of “nodular fasciitis”
in his local hospital. He also complained of moderate
fatigue and alopecia for 2 years. There was no family
history of other connective diseases. The physical examin-
ation showed that there was motor weakness with a power
of 2 of 5 in lower extremities and 3 of 5 in upper extremi-
ties. The sensory examination was normal. Deep tendon
reflexes were decreased and plantar reflexes were flexor.
The rest of the examination was unremarkable.
Laboratory assessment indicated a erythrocyte sedimen-
tation rate (ESR) of 79 mm/h. Urinalysis showed protein
in 3+, urinary sediment 0 to 2 red cells per 10*40 field and
no granular casts. Urine protein excretion was 7.00 g/24 h
and serum albumin was 1.8 g/dL. The results of the blood
cell count and hepatic function tests were normal. The
levels of serum creatinine, and urea nitrogen were nor-
mal, respectively, 68 μmol/L (range 57–97 μmol/L) and
3.8 mmol/L (2.6–7.5 mmol/L). Immunological screening
revealed an antinuclear antibody titer of 1:320, a speckled
pattern and a double-stranded DNA antibody titer of 1:20
positive. The rest of the autoantibody profiles, including
anti-smith, anti-ribonucleoprotein and antineutrophil
cytoplasmic antibodies, were negative. Serum C3 and C4
complement factors were low, respectively, 0.43 g/L (range
0.65–1.65 g/L) and 0.07 g/L (range 0.16–0.6 g/L). The
cerebrospinal fluid examination showed an increased pro-
tein concentration of 1.09 g/L and immunoglobulin (Ig) G
level of 0.28 g/L with a normal number of cells (white cell
count was zero). Electromyography revealed a severe
demyelinating polyneuropathy and a muscle biopsy re-
vealed neurogenic muscle damage.
Kidney biopsy was performed and revealed diffuse
thickening of the glomerular basement membrane
with “spike” formation, mesangial hypercellularity and
mesangial matrix expansion (Fig. 1). Immunofluores-
cence revealed 1 to 3+ global granular capillary wall
and mesangial staining for IgG, IgA, IgM, C3, C1q,
and fibrin-fibrinogen, which gave the characteristic
“full house” immunofluorescence for lupus nephritis.
The electron microscopic analyses showed numerous
subepithelial and mesangial electron-dense deposits,
as well as deposits within the glomerular basement
membrane with extensive fusion of foot processes.
The renal biopsy diagnosis was secondary membran-
ous nephropathy and suspected lupus nephritis. Two
biopsy specimens of nodular masses from the cheeks
were rechecked by our institution and revealed similar
features (Fig. 2); namely, diffuse mucinous material
deposited in the dermis with a moderate lymphocytic
and plasmacytic infiltrate in perivascular and periadnexal
tissue. Immunohistochemistry revealed IgG deposition at
the dermoepidermal junction. These findings were charac-
teristic of cutaneous PNM.
The patient was diagnosed as having SLE with manifest-
ation of class V lupus nephritis, GBS and PNM. He re-
ceived intravenous immunoglobulin therapy at 0.4 g/kg/d
for 5 days, then hydroxychloroquine 200 mg twice daily,
and an initial 1 mg/kg daily dose of prednisone and 0.8 g
cyclophosphamide once a month. At discharge, he had
partial recovery of his muscle strength in lower limbs
to 3/5 and upper limbs to 4+/5. After five cycles of
cyclophosphamide, his albumin level improved from
1.8 g/dl to 3.0 g/dl, urinary protein level fell from 7 g/
24 h to 2.3 g/24 h, ESR was 17 mm/h and levels of C3,
C4 increased to the normal range. He was able to walk
unassisted and had full recovery of his muscle strength
in all four limbs. Until now, he is still in follow-up
treatment and has not developed muscle weakness,
skin involvement or any other systemic manifestations
of lupus.
Fig. 1 Renal histopathological findings. Light micrographs of a glomerulus show diffuse thickening of the glomerular basement membrane
(Periodic acid-silver metheramine stain; 400×) (a) with mesangial hypercellularity and mesangial matrix expansion (Schiff periodic acid shiff stain;
400×) (b); electron microscopic analyses show numerous subepithelial and mesangial electron-dense deposits, as well as deposits within the
glomerular basement membrane with extensive fusion of foot processes (5000×) (c)
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Discussion
We describe here a SLE patient with PNM, GBS and
class V lupus nephritis. His skin nodules had not been
identified for 2 years until SLE was diagnosed. A combined
treatment with intravenous immunoglobulin, tapering
prednisone, hydroxychloroquine, and cyclophosphamide
successfully recovered his muscle strength and also in-
duced the partial remission of lupus nephritis.
Cutaneous mucinosis is a group of disorders charac-
terized by a prominent accumulation of mucin in the
interstitial spaces of the dermis, which are classified as
primary and secondary [5]. Some of the secondary muci-
nosis are associated with SLE, and may even be its initial
manifestation [5, 6]. PNM, also known as cutaneous
lupus mucinosis, is an uncommon disorder that typically
presents as asymptomatic skin-colored or pink-to-red
nodules or/and papules varying in size on the upper
parts including arms, head, neck, the back and the chest
[5]. There are rare reported cases of PNM occurring on
the lower extremities [7]. According to the literature [8],
the sex ratio of PNM is 11:13 (men:women). Considering
the female preponderance of SLE, 1:9 (men:women), the
male incidence of PNM is extremely high, and our
patient is male.
In patients with PNM, histopathologic examination re-
veals abundant deposits of mucin located primarily in
the papillary and mid-dermis, interspersed among colla-
gen bundles. There may be a slight perivascular lympho-
cytic infiltrate in the papillary dermis. The epidermal
changes in PNM are not the typical changes as seen in
specific LE lesions. Typical linear or granular deposits of
immunoglobulins (IgG and IgM) and C3 at the dermoe-
pidermal junction can be seen and are sufficient to con-
stitute a positive lupus band test [5, 9]. These deposits
are very similar to those seen in our patient.
The clinical manifestations of this patient with neuro-
psychiatric symptoms (GBS), skin (PNM and malar rash)
and renal involvement (class V lupus nephritis), and
laboratory assessments with hypocomplementemia, posi-
tive antinuclear and double-stranded DNA antibody,
satisfied 5 of 11 American College of Rheumatology
(ACR) criteria, and 3 clinical and 3 immunologic criteria
of the Systemic Lupus International Collaborating Clinics
(SLICC) criteria; accordingly, the patient was diagnosed as
having SLE. Nevertheless, he presented with PNM twice,
one and two years before admission, which probably cor-
responded to the initial presenting signs of SLE. PNM
may be in isolation or in combination with typical lesions
of LE. In one series, 80% of LE patients with PNM had
either joint or renal involvement [10], which underlines
high frequency of kidney involvement might occur in pa-
tients with SLE and having PNM. Our patient had class V
lupus nephritis confirmed by biopsy, which is much rarer
compared to Class III or IV nephritis in SLE.
Simultaneously, due to progressive symmetric numb-
ness, weakness and hyporeflexia of limbs and albumino-
cytologic dissociation of cerebrospinal fluid, he was
diagnosed as having GBS. To the best of our knowledge,
this case is the first reported case of PNM to be associ-
ated with GBS and lupus nephritis. GBS is an acute,
ascending, inflammatory, demyelinating polyneuropathy
and constitutes part of the ACR neuropsychiatric LE
case definition [11]. A retrospective series of 2097 pa-
tients with SLE in a 25-year study period showed only
one patient to have GBS [12]. By contrast, a study by
Leneman has reported seven patients out of a series of
1100 with GBS who had SLE [13]. GBS is therefore con-
sidered to be extraordinarily rare in SLE [12].
The response of PNM to treatment has been found to
be variable. In some cases, PNM lesions may remit spon-
taneously. Treatments that are used for LE, including anti-
malarials, or topical or oral corticosteroids have also been
used for PNM with variable results [14]. Injection of
lesions with hyaluronidase has also been reported to be
Fig. 2 Cutaneous histopathological findings. Light micrographs of a nodular mass biopsy specimen show diffuse mucinous material deposited in
the dermis (Alcian blue-schiff periodic acid shiff stain; 40×) (a) with a lymphocytic and plasmacytic infiltrate (confirmed by immunohistochemistry)
in perivascular and periadnexal tissue (Hematoxylin and eosin stain; 100×) (b)
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effective [15]. In this case, improvement of neurological
and renal manifestations with intravenous immuno-
globulin, prednisone and cyclophosphamide suggests an
autoimmune pathogenesis. We speculate that this may
represent a single or several cross-reactive autoanti-
bodies in neural and renal tissue. Furthermore, the
pathogenesis of PNM is also largely unknown. In our
case, PNM recurred 1 year after the first surgical resec-
tion of a nodule, and then the patient underwent the
second resection. To date, PNM has not relapsed but
we do not know if this is related to the drug treatment.
Presumably, common immunological pathways could
tie together these three manifestations.
Conclusions
In conclusion, the present case is the first case report
of PNM combined with GBS and class V lupus neph-
ritis in the background of SLE. In patients with PNM,
especially those with neurological symptoms and renal
involvement, clinicians should have a high index of sus-
picion for the presence of systemic diseases, especially
SLE.
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